TY - JOUR
T1 - Sirolimus-eluting versus uncoated stents in acute myocardial infarction
AU - Spaulding, Christian
AU - Henry, Patrick
AU - Teiger, Emmanuel
AU - Beatt, Kevin
AU - Bramucci, Ezio
AU - Carrié, Didier
AU - Slama, Michel S.
AU - Merkely, Bela
AU - Erglis, Andrejs
AU - Margheri, Massimo
AU - Varenne, Olivier
AU - Cebrian, Ana
AU - Stoll, Hans Peter
AU - Snead, David B.
AU - Bode, Christoph
PY - 2006/9/14
Y1 - 2006/9/14
N2 - BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P = 0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P
AB - BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P = 0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P
UR - http://www.scopus.com/inward/record.url?scp=33748702281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748702281&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa062006
DO - 10.1056/NEJMoa062006
M3 - Article
C2 - 16971716
AN - SCOPUS:33748702281
SN - 0028-4793
VL - 355
SP - 1093
EP - 1104
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 11
ER -